Results 41 to 50 of about 830,895 (193)

Entinostat-Bortezomib Hybrids against Multiple Myeloma

Molecules, 2023
Although proteasome inhibitors have emerged as the therapeutic backbone of multiple myeloma treatment, patients often relapse and become drug refractory. The combination between proteasome and histone deacetylase inhibitors has shown to be more efficient
Angelica Ferro, Dafni Graikioti, Emre Gezer, Constantinos M. Athanassopoulos, Muriel Cuendet   +4 more
doaj   +1 more source

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer [PDF]

, 2008
Background Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours.
Dietel Manfred, Fritzsche, Florian R., Weichert Wilko, Gekeler Volker, Dietel, Manfred, Fritzsche Florian R, Beckers Thomas, Kristiansen Glen, Jung, Klaus, Kristiansen, Glen, Weichert, Wilko, Jung Klaus, Scholman Katharina, Gekeler, Volker, Denkert Carsten, Röske, Annika, Röske Annika, Beckers, Thomas, Stephan, Carsten, Stephan Carsten, Scholman, Katharina, Denkert, Carsten Michael, Denkert, Carsten, Fritzsche, Florian R   +23 more
core   +1 more source

Epigenetics of cervical cancer. An overview and therapeutic perspectives

Molecular Cancer, 2005
Cervical cancer remains one of the greatest killers of women worldwide. It is difficult to foresee a dramatic increase in cure rate even with the most optimal combination of cytotoxic drugs, surgery, and radiation; therefore, testing of molecular ...
Cetina Lucely, Candelaria Myrna, Lizano Marcela, Dueñas-González Alfonso, Arce Claudia, Cervera Eduardo   +5 more
doaj   +1 more source

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer [PDF]

, 2016
Previous studies have associated the overexpression of histone deacetylase 2 (HDAC2) and the presence of TP53 mutations with the progression to advanced stage drug resistant colorectal cancer (CRC).
El-Bahrawy, M., Alzoubi, S, Brody, L., Silver, A, Bell, J, Hajji, N, Mercado, N., Mahul-Mellier, AL, Silver, A., Boobis, A., Mahul-Mellier, A.L., Bell, JD, Hajji, N., Mahul-Mellier, A-L, Bell, J.D., Rahman, S., Rahman, S, Boobis, A, Brody, L, Ito, K., Mahul Mellier, AL, Ito, K, Mercado, N, Alzoubi, S., El-Bahrawy, M, Alzoubi S, Bell JD, Hajji N, Ito K, Mahul-Mellier AL, Silver A, Boobis A, Brody L, Rahman S, Mercado N, El-Bahrawy M   +35 more
core   +1 more source

Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron [PDF]

, 2020
Histone deacetylase enzymes (HDACs) are responsible for the global silencing of tumour‐suppressor genes. Treatment with a histone deacetylase inhibitor (HDACi) can reverse this process and restore normal cell function. Herein, we report a small series of
Madeleine C. M. Gemmell, Rendina, Louis M., Louis M. Rendina, Kavianpour, Poya, Poya Kavianpour, Jan U. Kahlert, Kahlert, Jan U., Gemmell, Madeleine C. M.   +7 more
core   +1 more source

The deacetylase HDAC6 is an essential component of stress granules and plays a critical role in the cellular response to stress [PDF]

, 2007
The reversible acetylation of histones has a critical role in transcriptional regulation. Likewise reversible acetylation of non-histones proteins is also important for other cellular processes.
Kwon, So Hee
core   +1 more source

Histone deacetylase inhibitors in multiple myeloma

Hematology Reports, 2009
Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade.
Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken   +7 more
doaj   +1 more source

Macrocyclic Histone Deacetylase Inhibitors [PDF]

Current Topics in Medicinal Chemistry, 2010
Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have
Sandra C, Mwakwari, Vishal, Patil, William, Guerrant, Adegboyega K, Oyelere   +3 more
openaire   +2 more sources

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer

Frontiers in Oncology, 2022
Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemotherapy increase patient mortality.
Fengyi Guo, Hongjing Wang, Hongjing Wang
doaj   +1 more source

Pharmacogenomics and Histone Deacetylase Inhibitors [PDF]

Pharmacogenomics, 2016
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents.
Andrew Kl, Goey, Tristan M, Sissung, Cody J, Peer, William D, Figg   +3 more
openaire   +2 more sources